MDA 2026: Sevasemten Halts Functional Decline in Becker Trial

MDA 2026: Sevasemten halts functional decline in Becker trial

Becker muscular dystrophy (BMD) patients who received the experimental treatment sevasemten in clinical trials had stable motor function over several years of follow-up, new data showed. That stands in contrast to the typical progression of BMD, in which motor function steadily declines as the disease progresses. The data were presented at the Muscular Dystrophy Association (MDA)Clinical & Scientific Conference 2026, held March 8-11 in Orlando, …

Edgewise Therapeutics, a CureDuchenne funded company, announces positive long-term Sevasemten data in Becker muscular dystrophy patients.

Edgewise Therapeutics, a CureDuchenne funded company, today announced positive long-term Sevasemten data that demonstrated sustained functional stabilization in Becker Muscular Dystrophy (BMD) patients through 3.5 years of treatment. This result is in stark contrast to the functional decline expected from BMD natural history data.Today’s result is particularly important for BMD patients, an underserved population, who have no approved treatment …